CN103108637B - 静脉内施用格列苯脲和其他药物的方法 - Google Patents

静脉内施用格列苯脲和其他药物的方法 Download PDF

Info

Publication number
CN103108637B
CN103108637B CN201180044843.6A CN201180044843A CN103108637B CN 103108637 B CN103108637 B CN 103108637B CN 201180044843 A CN201180044843 A CN 201180044843A CN 103108637 B CN103108637 B CN 103108637B
Authority
CN
China
Prior art keywords
glibenclamide
drug
glyburide
hours
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180044843.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108637A (zh
Inventor
S·M·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remidi Pharmaceuticals
Original Assignee
Bicenza Chesa
Remidi Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicenza Chesa, Remidi Pharmaceuticals filed Critical Bicenza Chesa
Priority to CN201810945946.3A priority Critical patent/CN109172363A/zh
Publication of CN103108637A publication Critical patent/CN103108637A/zh
Application granted granted Critical
Publication of CN103108637B publication Critical patent/CN103108637B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
CN201180044843.6A 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法 Active CN103108637B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810945946.3A CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
PCT/US2011/044397 WO2012012347A2 (en) 2010-07-19 2011-07-18 Methods of intravenous administration of glyburide and other drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810945946.3A Division CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Publications (2)

Publication Number Publication Date
CN103108637A CN103108637A (zh) 2013-05-15
CN103108637B true CN103108637B (zh) 2018-09-14

Family

ID=45497399

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180044843.6A Active CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法
CN201810945946.3A Pending CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810945946.3A Pending CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Country Status (7)

Country Link
US (9) US8946293B2 (enExample)
EP (3) EP3339190A1 (enExample)
JP (5) JP6188021B2 (enExample)
KR (8) KR20230165363A (enExample)
CN (2) CN103108637B (enExample)
CA (3) CA2806069C (enExample)
WO (1) WO2012012347A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
CA2806069C (en) 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
HUE045889T2 (hu) 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
JP6092844B2 (ja) 2011-04-04 2017-03-08 バーグ エルエルシー 中枢神経系腫瘍の治療方法
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
MX381399B (es) * 2013-09-04 2025-03-12 Berg Llc Formulaciones de coenzima q10 y métodos de uso.
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
CN108348567B (zh) 2015-05-29 2022-03-01 马里兰州立大学巴尔的摩分校 减少或预防由内皮细胞的机械刺激所致的内膜损伤的方法
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN120004770A (zh) 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DE10300323A1 (de) * 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
ES2807274T3 (es) 2002-03-20 2021-02-22 Univ Maryland Un canal catiónico no selectivo en células neurales y compuestos que bloquean el canal para su uso en el tratamiento de la inflamación del cerebro
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
US10583094B2 (en) * 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
WO2006071781A2 (en) * 2004-12-23 2006-07-06 Hospira, Inc. Port closure system for intravenous fluid container
EP2071917B1 (en) 2006-09-29 2012-11-21 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CA2691199C (en) * 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
CN101229316B (zh) * 2008-01-31 2010-08-25 广东药学院 一种知母提取物
CA2806069C (en) 2010-07-19 2021-01-19 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用

Also Published As

Publication number Publication date
EP3586850A1 (en) 2020-01-01
JP2013532658A (ja) 2013-08-19
EP2595633A4 (en) 2014-01-22
CN109172363A (zh) 2019-01-11
KR20250026419A (ko) 2025-02-25
US10052280B2 (en) 2018-08-21
EP2595633A2 (en) 2013-05-29
KR20170118960A (ko) 2017-10-25
JP2016020393A (ja) 2016-02-04
KR20190031592A (ko) 2019-03-26
US20250221924A1 (en) 2025-07-10
US20170348227A1 (en) 2017-12-07
WO2012012347A3 (en) 2012-05-10
US10786445B2 (en) 2020-09-29
JP6795571B2 (ja) 2020-12-02
AU2011279878A1 (en) 2013-03-07
KR20230165363A (ko) 2023-12-05
CA2806069A1 (en) 2012-01-26
CN103108637A (zh) 2013-05-15
US20170333340A1 (en) 2017-11-23
EP3339190A1 (en) 2018-06-27
US10391053B2 (en) 2019-08-27
KR20220000943A (ko) 2022-01-04
US20190328653A1 (en) 2019-10-31
JP6506335B2 (ja) 2019-04-24
JP6179574B2 (ja) 2017-08-16
KR20180123176A (ko) 2018-11-14
US8946293B2 (en) 2015-02-03
KR20130133165A (ko) 2013-12-06
CA3225438A1 (en) 2012-01-26
JP2020073595A (ja) 2020-05-14
CA2806069C (en) 2021-01-19
JP6188021B2 (ja) 2017-08-30
US9561176B2 (en) 2017-02-07
US11559481B2 (en) 2023-01-24
US20130203853A1 (en) 2013-08-08
CA3101711A1 (en) 2012-01-26
US12226521B2 (en) 2025-02-18
US20210154135A1 (en) 2021-05-27
JP2019038855A (ja) 2019-03-14
CA3101711C (en) 2024-02-13
US20150157560A1 (en) 2015-06-11
US20230414489A1 (en) 2023-12-28
US9254259B2 (en) 2016-02-09
KR101917975B1 (ko) 2018-11-13
WO2012012347A2 (en) 2012-01-26
JP2017105846A (ja) 2017-06-15
KR20200054319A (ko) 2020-05-19
US20160030370A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
US12226521B2 (en) Methods of intravenous administration of glyburide
AU2011279878B2 (en) Methods of intravenous administration of glyburide and other drugs
HK40002343A (en) Methods of intravenous administration of glyburide and other drugs
HK40020325A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276B (en) Methods of intravenous administration of glyburide and other drugs
HK1185276A (en) Methods of intravenous administration of glyburide and other drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185276

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20180809

Address after: Massachusetts, USA

Applicant after: Bicenza Chesa

Address before: American New York

Applicant before: Remidi Pharmaceuticals

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240703

Address after: USA New York

Patentee after: Remidi Pharmaceuticals

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Bicenza Chesa

Country or region before: U.S.A.

TR01 Transfer of patent right